Observation Of Adjuvant Curative Effect Of Yiguanjian On Liver Damage Caused By Chemotherapy Of Bone And Soft Tissue Malignant Tumors Of Qi And Yin Deficiency Type

Purpose:In this study,a randomized controlled experiment was conducted to explore the observation of the adjuvant curative effect of Yiguanjian on the liver damage caused by chemotherapy of bone and soft tissue malignant tumors of Qi and Yin deficiency type,and to provide a clinical basis for traditional Chinese medicine for the treatment of liver damage caused by chemotherapy of bone and soft tissue malignant tumors.Method:A total of 60 patients with bone and soft tissue malignant tumors of Qi and Yin deficiency type who were admitted to the Department of Bone and Soft Tissue Oncology,Fuzhou Second Hospital from January 2020 to December 2021 were selected and randomly divided into the experimental group(polyene and soft tissue tumors).Phosphocholinesterase + Yiguanjian combined treatment)30 cases and the control group(conventional polyene phosphorylcholinesterase)30 cases.60 patients were diagnosed as malignant bone and soft tissue tumors(including osteosarcoma,undifferentiated sarcoma,Ewing’s sarcoma)according to the results of puncture and pathology,and they were systematically evaluated as drug-induced liver damage and qi-yin deficiency type drug-induced liver damage in line with Maria’s diagnostic criteria.TCM diagnostic criteria.The chemotherapy regimen for patients with osteosarcoma is epirubicin + cisplatin + methotrexate + ifosfamide(AP + M + I);the regimen for undifferentiated soft tissue sarcoma is epirubicin + cisplatin(AP +Endostat).);the chemotherapy regimen for Ewing sarcoma and Ewing-like malignant tumors is unified as vincristine + epirubicin + cyclophosphamide + ifosfamide +etoposide(VAC + IE),and the dose is converted according to the patient’s body surface area.The patients in both groups received routine liver-protecting therapy by intravenous drip of polyene phosphorylcholine ester at the beginning of chemotherapy,while the experimental group received Yiguanjian Modified and Subtracted Combined Liver-protecting therapy on the basis of routine therapy.Before treatment,the routine blood,urine and feces,liver function,TCM syndrome score and KPS score of the patients in the two groups were recorded respectively,and liver function indexes were detected every 2 days after the start of treatment.The average chemotherapy cycle of the patients was recorded,and the patients were followed up regularly during the discharge period.Conclusions were drawn by arranging and analyzing the data.Result:Neither the experimental group nor the control group were eliminated or dropped.Finally,60 eligible patients were included,30 in the control group and 30 in the experimental group.There were no significant differences in gender,age,cisplatin content,KPS score before chemotherapy,tumor type and other items between the two groups(P>0.05).There was significant difference(P<0.01),and the difference in the improvement of clinical symptoms between the two groups after treatment was statistically significant(P<0.01).Conclusion:Yiguanjian combined with polyene phosphorylcholinesterase liver protection therapy has a certain auxiliary effect on liver damage caused by chemotherapy of bone and soft tissue malignant tumors of Qi and Yin deficiency type.The drug has high safety.There is a positive effect on the improvement of student performance.